5.30
+0.05(+0.95%)
Currency In USD
Address
2100 West Loop South
Houston, TX 77027
United States of America
Phone
800 946 9185
Website
Sector
Healthcare
Industry
Biotechnology
Employees
4
First IPO Date
November 08, 2019
| Name | Title | Pay | Year Born |
| John Michael Climaco | Chief Executive Officer, President & Director | 810,863 | 1969 |
| Sandra L. Silberman | Chief Medical Officer | 288,436 | 1955 |
| Christopher S. Downs FP&A | Chief Financial Officer | 474,640 | 1978 |
| Donald H. Picker | Chief Science Officer | 0 | 1946 |
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc. The company was incorporated in 2017 and is based in Houston, Texas.